Anson Funds Management’s Lipocine LPCN Stock Holding History

Anson Funds Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,259	Closed	-$8K	–	90
2019 Q4	$8K	Buy	+1,259	New	+$32.2K	0.01%	81

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FPCG

Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Anson Funds Management's LPCN Position: Q1 2020 in Review

Anson Funds Management sold out of Lipocine (LPCN) in Q1 2020, closing a stake of 1,259 shares — an estimated $8K sold.

Anson Funds Management first reported a position in LPCN in Q4 2019 and held it in 1 quarter. The position peaked at $8K in Q4 2019. 28 funds tracked by Wall St. Rank hold LPCN as of Q1 2020.

Anson Funds Management reported no remaining Lipocine position as of Q1 2020 after selling out during the quarter.
Anson Funds Management sold 1,259 Lipocine shares in Q1 2020, an estimated $8K.
Anson Funds Management first reported a position in Lipocine in Q4 2019 and held it in 1 quarter.
Anson Funds Management's Lipocine position peaked at $8K in Q4 2019.
28 funds tracked by Wall St. Rank held Lipocine as of Q1 2020.

Based on Anson Funds Management's 13F filing for Q1 2020, filed 15 May 2020.